REFERENCES
- Denton M, Kerr KG. Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clin Microbiol Rev 1998; 11 (1): 57–80.
- Vartivarian SE, Papadakis KA, Palacios JA, Manning JT, Anaissie EJ. Mucocutaneous and soft tissue infections caused by Xanthomoans maltophilia: a new spectrum. Ann Intern Med 1994; 121 (12): 969–973.
- del Toro MD, Rodriguez-Bano J, Herrero M, et al. Clinical epidemiology of Stenotrophomonas maltophilia colonization and infection: a multicenter study. Medicine 2002; 81 (3): 228–239.
- del Toro MD, Rodriguez-Bario J, Martinez-Martinez L etal. Epidemiology, clinical features and prognosis of infections due to Stenotrophomonas maltophilia. Enferm Infecc Microbiol Clin 2006; 24 (1): 4-9.
- Muder RR. Optimizing therapy for Stenotrophomonas maltophilia. Semin Respir Crit Care Med 2007; 28 (6): 672–677.
- Nicodemo AC, Paez JI. Antimicrobial therapy for Stenotrophomonas maltophilia infections. Eur J Clin Microbiol Infect Dis 2007; 26 (4): 229–237.
- Shakil S, Akram M, AU, Khan. Tigecycline: a critical up-date. J Chemother 2008; 20 (4): 411–419.
- Milatovic D, Schmitz FJ, Verhoef J, Fluit AC. Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent Eu-ropean clinical bacterial isolates. Antimicrob Agents Chemother 2003; 47 (1): 400–404.
- Sader HS, Jones RN, Dowzicky MJ, Frirische TR. Antimi-crobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit. Diagn Microbiol Infect Dis 2005; 52 (3): 203–208.
- Betriu C, Rodríguez-Avial I, Sánchez BA, Gómez M, Pi-cazo JJ. Comparative in vitro activities of tigecycline (GAR-936) and other antimicrobial agents against Stenotrophomonas mal-tophilia. J Antimicrob Chemother 2002; 50 (5) :758–759.